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3My warmest greetings to all! 
Not long after the “birth” of new Malaysia 
(post 9 May), the prestigious journal 
Nature in its June 2018 issue highlighted 
Malaysia (i.e., University of Malaya) as 
being on par with Hong Kong, Singapore, 
South Korea and Taiwan in its research 
capacity. These are the five East Asian 
countries with world leading institutions 
based on international rankings and 
MESSAGE FROM THE DEPUTY DEAN
PROFESSOR DR YVONNE LIM AI LIAN
DEPUTY DEAN (RESEARCH)
message from the deputy dean
publication statistics. The article also identified Malaysia as a world 
leader in encouraging women to participate in science.
This third issue of Pulse@UM begins with the research journey of two 
prominent parasitologists. If you missed the enlightening inaugural 
lectures of these two parasitologists on worms and malaria parasites 
respectively, the Our People, Our Story section brings you a summary 
of their exciting work on these parasites.
As we approach the month of October, which is the Cancer Awareness 
month, we would like to highlight the whole gamut of cancer 
research-related activities in our faculty which cover fundamental 
research,translational research and research that utilises 
nanotechnology.
We are also proud to highlight the story of a successful multi-
agency collaboration. Project ROSE (Removing Obstacles to cervical 
ScrEening), led by University of Malaya, was shortlisted as one of 
the three finalists for the 2018 UICC (Union for International Cancer 
Control) Collaborative Award. This prestigious award recognises 
collaborative initiatives, whether national, regional or international 
thatexhibit innovative models of engagement and outcomes.
Lastly, we would like to congratulate all the award winners. The 
dynamism of our faculty students and staff is once again recognised 
at the national and international arena. With that, I would like to leave 
you with this quote, “It is amazing what you can accomplish if you 
do not care who gets the credit” by the late Harry S. Truman (33rd 
President of United States).
Hope you enjoy this issue.
With best wishes,
Professor Dr Yvonne Lim Ai Lian
Pulse@UM is a tri-annual research bulletin 
in English published by the Faculty of 
Medicine at the University of Malaya. 
The views and opinions expressed here 
are those of the author(s) and do not 
necessarily reflect those of UM, and the 
editorial board. Materials from the Bulletin 
may be reprinted with proper attribution.
If you would like to learn more about 
anything from this bulletin, or would 
like to contribute or subscribe to future 
issues, please get in touch with us at 
editorialpulse@um.edu.my.
For the online version of this bulletin, visit:
https://resfom.um.edu.my/pulse@UM
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OUR PEOPLE, OUR STORY
PROFESSOR DR YVONNE LIM AI LIAN: DEBUNKING THE MYTH ABOUT GUT 
WORMS BY UNLOCKING THE SECRETS OF GUT MICROBIOTA
On 5 April 2018, Professor Dr Yvonne Lim Ai Lian delivered her inaugural and ASM 
fellows’ lecture entitled “Debunking the myth 
about gut worms by unlocking the secrets of 
gut microbiota” at the TJ Danaraj Auditorium, 
Faculty of Medicine. 
The auditorium was packed with current and 
former colleagues, collaborators from various 
private and public universities and government 
agencies, students, friends, well-wishers and 
family members. Members of the Academy of 
Sciences Malaysia (ASM) and the Malaysian 
Society of Parasitology and Tropical Medicine 
(MSPTM) also graced this occasion. 
In the words of Professor Dato Dr Adeeba 
Kamarulzaman, our Dean, the brilliant lecture 
kept everyone enthralled for one hour on the 
subject of worms, of all things!
Professor Yvonne joined the Department of 
Parasitology, Faculty of Medicine, University 
of Malaya in November 2003. Prior to this, 
she lectured at the Faculty of Science and 
Technology, Universiti Kebangsaan Malaysia 
(UKM) and Tunku Abdul Rahman College (now 
Tunku Abdul Rahman University College).
 
Her passion is in teaching and nurturing 
students. To date, she has supervised more 
than 30 postgraduate students. With the many 
years of experience in teaching parasitology, 
she recently co-authored the book “Medical 
Parasitology: A textbook” which was published 
by Springer (2018). Besides teaching, she is 
also a keen researcher. Her research focuses 
on neglected tropical diseases, primarily 
among marginalised populations (e.g., Orang 
Asli communities, migrant workers). One of her 
greatest satisfactions in being a researcher is 
the opportunity to work alongside the Orang 
Asli community. This scientific endeavour 
with the Orang Asli community has been 
more than an intellectual pursuit for her. Over 
the years, the experience has unfolded a 
deep sense of appreciation for humanity and 
provided invaluable opportunities to give back 
to society, especially to these disadvantaged 
communities. 
Although Professor Yvonne has received 
numerous awards, recognitions and was even 
recently featured as one of the 10 Science 
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Stars of East Asia, she remains grounded and 
humble about her achievements. The following 
is a summary of her heartwarming story which 
she delivered with much humour, passion 
and sincerity.
In her recent UM inaugural lecture and ASM 
Fellow’s lecture, Professor Yvonne took us on 
a journey of discovery to unlock the secrets of 
gut worms and microbiota. Gut worms such 
as Ascaris lumbricoides, Trichuris trichiura, 
and hookworm have always been associated 
with poor health, which is why deworming 
programmes are conducted worldwide to 
eradicate these worms from our human gut. 
However, in recent years, there is a growing 
interest in using worms as therapeutic agents for 
inflammatory diseases.
Her journey to unravel the secrets of these 
worms started in 2007, when her team 
conducted a comprehensive study on the status 
of worm infections among the indigenous 
(Orang Asli) communities residing in Peninsular 
DEBUNKING THE MYTH ABOUT GUT 
WORMS BY UNLOCKING THE SECRETS 
OF GUT MICROBIOTA
Malaysia. Although some communities were 
already exposed to development, it was 
found that worm infections still persisted 
in the indigenous population with an overall 
prevalence of 73.2%. These results were then 
presented to the Director of the Department of 
Orang Asli Development (JAKOA) in 2010 and 
following the outcome of the National Action 
Council (MKN) in that same year, deworming 
programmes were re-initiated, benefitting 
approximately 1600 Orang Asli. This was a 
significant action by the government agency 
as large scaled deworming programmes have 
been discontinued in Malaysia since 1983. 
To empower these communities to take 
ownership of their health issues, a health 
education project, aptly named HELP (Health 
Educational Learning Package) was developed 
and initiated, which involved school teachers, 
school children, and villagers. Coupled with 
deworming treatments, the programme was 
effective in decreasing the number of infections 
as well as the parasite load in infected 
individuals. Based on post-intervention 
evaluation, knowledge that was imparted to 
the school children was carried home to their 
Professor Yvonne, her students and team members at her recent 
UM inaugural lecture and ASM Fellow’s lecture.
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siblings and parents.
Given that resources to provide deworming 
programmes are scarce, Professor Yvonne 
and her team decided to utilise the Geographic 
Information System (GIS) technology to 
create a predictive map of worm infections. 
This tool was also able to estimate the number 
of individuals that needed to be treated with 
deworming drugs in 78 districts across 
Peninsular Malaysia. This effort enabled 
evidence-based decision making and assisted 
in the implementation of sustainable and cost-
effective worm infection control programmes 
by the Ministry of Health.
Along the way, an intriguing finding was 
observed which led Prof Yvonne’s research 
team down a new path. There was evidence 
in one of their studies that low prevalence 
of confirmed bronchial asthma (i.e., 1.4% of 
716) was observed in communities with high 
prevalence of worm infections (i.e., 73.2% of 
716). This observation was interesting as it 
highlighted that worms and their products 
have potential to provide protection against 
some diseases. 
Around the same time, Prof Yvonne was 
approached by New York University 
researchers who were interested in evaluating 
the use of worms as a therapeutic agent 
for diseases such as inflammatory bowel 
diseases (IBD).  After four years of toil and 
sweat, their team finally discovered a possible 
pathway that enables gut worms to potentially 
treat inflammatory bowel diseases (IBD) such 
as Crohn’s Disease and ulcerative colitis. 
Their work, which was published in SCIENCE, 
discovered that infection with gut worms 
in mice model of Crohn’s disease increased 
the number of Clostridia bacterial species, 
which are known to be “anti-inflammatory”, 
and decreased the abundance of Bacteroides: 
bacteria which are thought to promote IBD, as 
much as a thousand-fold. 
In addition, their team simultaneously 
conducted a human field cross-sectional study 
and found that Trichuris-infected individuals 
in rural Malaysia have higher microbial 
diversity than Trichuris-negative individuals. 
By conducting a pilot longitudinal treatment 
study, stool samples collected from 75 
infected individuals were analysed before and 
after deworming treatment with albendazole. 
Consistent with the earlier cross-sectional 
study, the diversity of microbial communities 
was significantly reduced after deworming 
and Clostridiales were the most significantly 
reduced order, whereas Bacteroidales 
(Prevotella) were significantly expanded after 
treatment. These findings were among the first 
to uncover the mechanisms by which worms 
could be potentially used as a therapeutic 
agent for IBD. 
In their on-going study, they will be assessing 
the effects of deworming drug treatment in 
humans on the gut microbiota by metagenomics 
analysis. Along with dietary surveys, the 
proposed field studies will provide longitudinal 
analyses of worm-infected individuals to 
establish cause and effect relationship of gut 
worms on the gut microbiota composition and 
function. The team hopes to find strategies to 
improve deworming efficacy in communities 
that require deworming, and to develop new 
therapeutic strategies for manipulating 
the microbiota in individuals suffering 
from inflammatory diseases caused by 
microbial dysbiosis.
7Professor Dr Fong Mun Yik obtained his PhD 
degree from University of Malaya in 1996. He 
joined the Department of Parasitology, Faculty 
of Medicine, University of Malaya (UM) in 1998 
as a junior lecturer. He was promoted to the 
position of Associate Professor in 2003, and 
obtained full Professorship in 2008.
Professor Fong’s main research interest is in 
molecular parasitology, especially in the areas 
of molecular epidemiology and development 
of recombinant antigens for serodiagnosis 
of parasitic infections. In addition, he is 
also interested in dengue virus research, 
particularly the molecular aspect of the virus. 
As a senior scientist, he has also been very 
active in various academic societies and 
editorial boards of scientific journals. 
At the administrative level, Professor Fong 
has contributed in various ways to improve 
the quality management system of the faculty 
and the university by serving as the Head of 
Documentation Unit, QMEC Deputy Director and 
Senior Lead Auditor for Quality Management 
System at various times. 
Despite the various awards and high 
achievements obtained, Professor Fong 
remains a friendly and approachable person to 
colleagues and students. He is always known 
for his humour and enthusiasm in sharing his 
knowledge. In his recent inaugural lecture titled 
“The intriguing malaria parasite Plasmodium 
knowlesi: monkey, man, ‘spy’ & double identity”, 
he took us through his exciting journey of 
research on various medically important 
parasites, in particular the 5th human malarial 
parasite, Plasmodium knowlesi that later 
became the core subject of his research. 
The series of Professor Fong’s studies on P. 
knowlesi culminated in the discovery of two 
genetically distinct types of the parasite, one 
mapping to Peninsular Malaysia and the other 
to Malaysian Borneo. In the lecture, he shared 
with the audience the fundamental aspects of 
the discovery and the medical implications of 
his findings, summarized as follows.
our people. our story
PROFESSOR DR FONG MUN YIK: THE INTRIGUING MALARIA PARASITE PLAS-
MODIUM KNOWLESI: MONKEY, MAN, ‘SPY’ & DOUBLE IDENTITY
DIMORPHISM OF P. KNOWLESI PROTEINS
Invasion of a malaria parasite into its host 
erythrocyte depends on the interaction between 
the parasite’s protein and the corresponding 
receptor of the erythrocyte. Plasmodium 
knowlesi uses the Duffy blood group antigen 
as a receptor to invade erythrocytes. The 
Duffy binding protein of P. knowlesi (PkDBP) 
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is encoded by an α-gene, where its region II 
is known as PkDBPαII. Professor Fong first 
revealed through nucleotide sequence analysis 
that there is a high level of genetic diversity 
in PkDBPαII of the parasite from Malaysia. 
At the protein level, more than 30 PkDBPαII 
haplotypes were clustered into two distinct 
groups, for which the majority were clustered 
into a large dominant group. Subsequently, 
through phylogenetic analysis, Professor 
Fong showed that there was an equally high 
diversity of PkDBPαII in Malaysia Borneo, but 
the haplotype group was distinct from that of 
Peninsular Malaysia.
Subsequent to the binding of the P. knowlesi 
merozoite to the erythrocyte, the parasite 
pulls itself into the erythrocyte simultaneously 
creating a parasitophorous vacuole (PV) that 
separates it from the host-cell cytoplasm. The 
rhoptry-associated protein RAP-1 is one of the 
mediators that are involved in the invasion 
process, and it has been postulated that genes 
encoding RAP-1 are highly conserved in all 
Plasmodium species. Nonetheless, Professor 
Fong’s study using a larger sample size of 
recent P. knowlesi isolates revealed that there is 
indeed high genetic polymorphism in PkRAP-1. 
Furthermore, PkRAP-1 could be separated into 
two Peninsular Malaysia and Malaysian Borneo 
haplotypic groups, thus, providing evidence of 
two distinct P. knowlesi types.
DIVERGENCE OF THE CIRCUMSPOROZOITE 
PROTEIN (CSP) REPEAT REGION MOTIFS
Besides efforts to elucidate the genetic basis 
and pathophysiology of malaria, Professor 
Fong also researches on effective vaccine 
to combat this deadly disease. A number 
of vaccines have been developed against P. 
falciparum. Most of them were based on the 
circumsporozoite protein (CSP), which is the 
most abundant and immunodominant protein 
on the sporozoites of Plasmodium species. 
In contrast to the homogenous repeat motifs 
of P. falciparum and P. vivax, Professor Fong 
found that the P. knowlesi CSP repeat region 
is hyperpolymorphic. He discovered more 
than 60 different types of motifs with different 
lengths and compositions. Some of the motifs 
are common, i.e., found in P. knowlesi isolates 
from both Peninsular Malaysia and Malaysian 
Borneo. Others are found only in Peninsular 
Malaysia and are absent in Malaysian Borneo 
or vice versa. This hyperpolymorphic nature of 
the P. knowlesi CSP is likely a major obstacle 
in the development of a CSP-based vaccine for 
knowlesi malaria.
ULTIMATE PROOF OF GENETIC DICHOTOMY
In order to determine whether the P. knowlesi 
in Malaysia has differed and independently 
become zoonoses, Professor Fong’s team 
focussed on two genes that have been 
extensively used for phylogenetic studies: 
the mitochondrial encoding the cytochrome 
oxidase subunit I protein (PkCOX1) and the 
nuclear encoding small subunit ribosomal 18S 
RNA (Pk18S rRNA). The results strongly support 
the conclusion that the two geographically 
separated regions (Borneo and Peninsular 
Malaysia) of this country harbour genetically 
distinct P. knowlesi populations. 
Although P. knowlesi from the two geographic 
regions were genetically differentiated, there 
was a very low genetic differentiation between 
the human and macaque parasites in the 
regions, indicating that humans are susceptible 
to infection by any of the P. knowlesi types 
circulating in macaques and the P. knowlesi 
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types became zoonotic independently in the 
two regions.
IMPLICATION OF P. KNOWLESI GENETIC 
DICHOTOMY ON DISEASE SEVERITY
Plasmodium knowlesi is now the major cause 
of human malaria in Malaysia. The cases 
in Malaysian Borneo have a higher rate of 
severe (up to 39%) and fatal infections (up to 
27%), which are not commonly observed in 
Peninsular Malaysia. Clinical symptoms of 
malaria are primarily attributed to the blood-
stage of the parasite life cycle, which results 
from repeated rounds of erythrocyte invasion, 
erythrocyte lysis and release of free merozoites. 
Severity in malaria is multifactorial in nature, 
while the genetic factor of the parasite is an 
important contributing factor. 
Professor Fong postulated that enhanced 
virulence and multiplication of the parasite 
are the result of genetic polymorphisms that 
increase THE invasion ability of the parasites 
into human erythrocytes. His team now 
continues to investigate P. knowlesi erythrocyte-
invasion genes, in the quest for genetic 
evidence that the Malaysian Borneo P. knowlesi 
has evolved into a more virulent form of this 
intriguing parasite.
Professor Fong and his research team at the Department of Parasitology, Faculty of Medicine.
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Advance care planning (ACP) - defined as “a process that aids a person regardless 
of their age and health status to understand 
and share their personal values, life goals 
and preferences toward future medical care” 
- is one of several strategies implemented 
in developed countries to promote active 
ageing. Based on the principle of autonomy, 
ACP ensures that care is concordant with a 
patient’s wishes, particularly when patients 
lose the capacity to decide on end-of-life care. 
ACP leads to an advance directive – otherwise 
known as a “living will”. A living will legally 
documents a patient’s preference of medical 
treatments for “end-of-life” (a terminal phase 
when a patient is dying a predictable death) 
and appoints a proxy decision-maker.
Family members of those who had an advance 
directive reported less emotional stress, less 
depression and better quality of life compared 
to those who did not. Well implemented ACP 
policies reduce healthcare cost for terminally ill 
patients. However, despite the known benefits 
of ACP and the existence of legislative support 
for ACP in developed countries, the uptake of 
ACP remains low.
Decision making regarding ACP is complex 
and multifaceted, reflecting the conflicting 
needs and perception of end-of-life care among 
patients, healthcare professionals, and health 
care systems. Personal values, age, education 
level, stress, timing, environment, health status, 
knowledge, as well as the relationship with 
physicians, family, and proxies are factors that 
affect decision making regarding ACP. Race, 
religion, and cultural values also influence 
attitudes towards ACP.
Studies on ACP have been performed primarily 
CONNECT THE WORLD
ARE PRIMARY CARE PHYSICIANS AND AMBULATORY PATIENTS IN MALAYSIA 
READY FOR ADVANCE CARE PLANNING? 
ASSOC PROF DR PAULINE LAI SIEW MEI
DEPT OF PRIMARY CARE MEDICINE
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in cognitively impaired, older or seriously 
ill patients (such as patients with cancer, 
heart failure, or end-stage renal disease). 
The majority of these studies assessed the 
readiness of patients and proxies to engage 
in conversation regarding ACP and whether 
they would write an advance directive. With 
cancer patients, most physicians preferred 
to postpone the conversation regarding ACP 
to later in the illness trajectory, when patients 
had a major change in functional status, when 
poor prognosis is certain or when treatment 
options are exhausted. This reflects the 
physicians’ belief that patients would simply 
not be interested in ACP until the issues 
are relevant.
Overall, available literature suggests that all 
stakeholders were reluctant to engage in ACP 
at an earlier time-point and preferred to dawdle 
until the issues were more clinically relevant 
and salient. Under normal circumstances, 
patients would have more time for non-
pressured deliberation. In comparison, not 
many studies have been conducted among 
primary care physicians and ambulatory 
patients. However, if ACP is left till a later 
point in time, a patient may be pressured into 
making an ill-informed decision.
Currently, ACP is not legislated in Malaysia. A 
qualitative study performed among 15 older 
people (aged 65–83 years) in Malaysia found 
that they have never heard of ACP but were 
receptive to its concept. This observation 
concurred with another study conducted 
among 56 Malaysian patients undergoing 
haemodialysis which reported that 76% of 
patients have never heard about ACP.
As part of the “Enabling Malaysian to Actively 
Age Study” (EMAAS) program (funded by 
the University Malaya Research Grant), the 
University of Malaya Primary Care Research 
Group has developed and validated an 
instrument - the Advance Care Planning 
Questionnaire - to assess the knowledge, 
attitude, and practice of ACP in Malaysia. The 
Advance Care Planning Questionnaire has been 
validated in English. We have translated this 
instrument to Malay, and have completed its 
validation. We plan to use both the English and 
Malay versions of the Advance Care Planning 
Questionnaire to assess the knowledge, attitude 
and practice of Malaysians towards ACP, and to 
determine if Malaysians are ready for ACP.
Additionally, there is a gap in the literature 
regarding the views of Asians on ACP. 
Geographically, Asia is the largest continent 
in the world, and has the highest population. 
A better understanding of the views of Asians 
and those that have migrated (i.e. the effect of
acculturation) can help policy makers navigate 
through the culturally-sensitive issues in the 
implementation of ACP in Asian or culturally-
diverse countries. Hence, a systematic review 
on Asian views on ACP and the effect of 
acculturation will be conducted.
In addition, a qualitative study will also be 
conducted to identify barriers and facilitators 
of primary care physicians and ambulatory 
patients on when would be the best time to 
initiate a conversation regarding ACP. It is 
our hope that findings from these studies will 
guide policymakers on whether ACP should be 
legislated in Malaysia.
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“The UM urology research unit enjoys a close 
working relationship between urologists and 
scientists across nations. It has continued to 
flourish and produce numerous human capitals 
over the past decades through both national 
and international collaborations, enabling basic 
research findings to be translated into benefit for 
patients and vice versa.”
Uncontrollable growth of abnormal cell 
potentially invades and spreads to other 
body parts in the form of cancer. Urological 
cancers can develop in organs such as the 
bladder, kidney, prostate and testicles. Similar 
to other cancers, it is often unpredictable and 
can differ markedly across different racial 
and ethnic groups, leading to the different 
pathophysiologies of the disease and treatment 
outcomes. To date, the understanding of 
the development of cancerous cells remain 
challenging, nevertheless, continuous effort 
is the key to unlock the unknown. With the 
passion of working on urological cancers, 
here, in Faculty of Medicine (FOM), research 
into the “ABC” is in full swing. The researchers 
are working from various aspects, looking into 
the genetics of cancer patients, searching for 
risk factors and genetic variants related to 
the increased risk of an individual to develop 
urological cancer, particularly in a multi-
ethnic Asian population. The use of potential 
biomarkers obtained from the DNA databases 
has greatly improved the risk prediction for 
early detection that brings the prospect of 
a comprehensive DNA screening test and 
new treatments closer to reality, improving 
treatment and patient care.
research spotlight
PROFESSOR DR AZAD RAZACK
PROFESSOR DR ONG TENG AIK
DR JASMINE LIM
DR RETNAGOWRI RAJANDRAM
DEPARTMENT OF SURGERY
RESEARCH SPOTLIGHT
THE ABC’S OF UROLOGICAL CANCER RESEARCH: (A = PROSTATE CANCER; B = 
BLADDER CANCER; C = RENAL CELL CARCINOMA)
Professor Azad and Dr Jasmine attended and initiated the prostate cancer research collaboration with the 
PRACTICAL consortium during its annual meeting in London, 2013.
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Prostate cancer has developed into the fifth 
commonest cancer diagnosed in Malaysian 
men in 2017. In 2013, the group leader Professor 
Dr Azad Razack initiated an international 
collaboration with PRACTICAL (Prostate 
Cancer Association Group to Investigate 
Cancer Associated Alterations in the Genome) 
consortium, which provided us with access to 
genetic prostate cancer samples from over 100 
research groups worldwide. The collaboration 
has successfully identified 63 new genetic 
variations in high-risk populations (Nature 
Genetics, 2018; Nature Communications, 
2018). Besides, The Malaysian Prostate 
Cancer (M-CaP) Study initiated in 2016, co-led 
by Associate Professor Dr. Ong Teng Aik and Dr. 
Jasmine Lim is also one of the efforts taken to 
increase the understanding of prostate cancer 
epidemiology. This inaugural prostate cancer 
registry in Malaysia is collaborating with 8 
Ministry of Health Hospitals with the support 
of Malaysia National Institute of Health (NIH) 
and University of Tokyo, Japan. To date, the 
study has recruited more than 1,100 newly 
diagnosed prostate cancer cases nationwide.
 
With bladder cancer as the ninth commonest 
cancer worldwide, the urology bladder 
cancer research team, led by Associate Prof 
Dr Shanggar Kuppusamy is researching on 
the roles of histone modification proteins 
in bladder cancer. The team is exploring the 
protein and gene expressions of H3 lysine 27 
(H3K27) demethylases and their significance 
in bladder cancer, in hopes of using it as 
tumour biomarkers for the early detection or 
recurrence prediction for the disease. This 
collaborative project is being carried out 
with the Department of Pathology, University 
of Malaya and University of Queensland, 
Australia. Another key interest of the team is 
to create an accurate and complete bladder 
cancer database in Malaysia, starting with 
University Malaya Medical Centre (UMMC) 
patient pools.
Renal cell carcinoma (RCC) is one of the least 
known cancer types, but can cause significant 
mortality if not well treated. To address the 
knowledge gaps, the RCC research team 
works with other affiliates from the Faculty 
of Medicine especially from Pathology and 
Oncology via Associate Professor Dr Ong 
Teng Aik and Dr Retnagowri Rajandram, with 
long-term close collaboration with the Centre 
for Kidney Disease Research at Translational 
Research Institute, University of Queensland. 
The research established the Malaysian RCC 
cell lines as a potential in vitro tool for the 
study of RCC by Dr Yap Ning Yi. 
BLADDER CANCER
RENAL CELL CARCINOMA
Gowri (left) and Glenda (right). The photo was taken at 
Pavillion, Kuala Lumpur during Glenda’s visit to Malaysia.
PROSTATE CANCER
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The team has also initiated the collection of biological samples from RCC patients at UMMC and 
the growing repository of biological samples serves as an important source of research material 
for the evaluation of biomarkers in the serum and tumour tissue. These research discovered 
several promising biomarker proteins regulating cell apoptosis and proliferation such as TNF 
receptor-associated factor 1 (TRAF1) and nuclear factor kappa-light-chain-enhancer of activated 
B cells (NF-κB), as well as the immune response protein, cluster of differentiation 14 (CD14). On 
the other hand, the research is paving the way towards investigating the link between obesity 
and RCC, specifically by investigating leptin and its receptor, both of which take part in regulating 
hunger and energy expenditure. It is believed that the study will provide a clue into the molecular 
profiling and pathway analysis of clinically aggressive RCC. Overall, these studies address 
both fundamental and clinical issues in the form of translational research work in the hope of 
improving patient treatment and management. 
For further details regarding urological cancer research, please kindly contact Prof. Dr. Azad Razack 
at azadrazack@gmail.com
The UM Urology Group.
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In the late 1970s, survival of children with acute lymphoblastic leukaemia (ALL), the 
commonest childhood cancer, in UMMC was 
reported to be between 30-40% (Sinniah, 1978). 
The adoption of the German BFM protocols in 
the mid-1980s with intensive chemotherapy 
and prophylactic cranial irradiation increased 
overall survival (OS) to 56% (Ng, 2000). In 2003, 
with the founding of the Malaysia-Singapore 
(MASPORE) Leukemia Study Group, the 
MASPORE-ALL2003 protocol was launched, 
incorporating cytogenetics and PCR-based 
minimal residual disease monitoring to deliver 
risk-adapted therapy to affected children. The 
trial closed in 2010, (n=556) and significantly 
improved OS for all risk categories to 81% 
(Yeoh, 2012). 
Modern therapies have also elevated survival 
rates to 75-80% for children with various other 
cancers such as Wilms’ tumour, lymphoma 
and hepatoblastoma.  However, these stellar 
achievements have come at a price. Many 
childhood cancer patients survive decades 
after completing treatment but experience 
premature development of chronic health 
conditions. A phenotype of accelerated ageing 
in these survivors with co-morbidities such 
as ischemic heart disease, diabetes mellitus, 
chronic renal failure, and frailty in their early 
forties is particularly striking (Bhakta, 2017). 
Clearly, paediatric oncologists have a central 
role in leading research to elucidate the 
effects of cancer and its treatment on growth, 
development, cognition, and overall health in 
these young adult survivors. 
Our own studies on childhood cancer 
survivors (CCS) have revealed similar 
concerns. Although predominantly in their 
mid-20s and asymptomatic, we found that our 
Malaysian CCS  cohort (n=101) had a cellular 
PROFESSOR DR HANY ARIFFIN
DEPARTMENT OF PAEDIATRICS
WHEN A CURE IS NOT ENOUGH: ADDRESSING CHALLENGES IN TREATING 
CHILDHOOD CANCER 
The paediatric oncology team of clinicians and scientists in UMMC, 
led by Professor Hany Ariffin (second from the right).
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phenotype of senescence, inflammation, and 
telomere shortening similar to that observed 
in individuals three decades older. One in 
five of our survivors had already developed 
overt metabolic syndrome, whereas 50% 
demonstrated >1 abnormal metabolic 
parameters such as hypertension, dyslipidemia 
or elevated blood glucose (Ariffin, 2017). 
Whilst a high survival rate is the aim and 
source of pride for every paediatric oncologist, 
an ever-increasing pool of young adult CCS 
with debilitating chronic co-morbidities 
necessitates serious reconsiderations 
on treatment philosophy. One of the key 
mitigation strategies is to re-think how these 
children are treated. Specifically, risk-adapted 
chemotherapy protocols with avoidance of 
irradiation, identification of novel molecular 
targets, and incorporation of small molecules 
are continuously being designed and improved 
to minimize long-term organ toxicities as 
much as feasibly possible.
Prophylactic cranial radiotherapy, once 
a standard component of childhood ALL 
therapy, has almost universally been replaced 
by intrathecal and systemic methotrexate to 
reduce radiation-associated late effects. In 
the MASPORE-ALL2003 protocol, only 15% of 
patients received irradiation. The MASPORE-
ALL2010 clinical trial (currently has recruited 
approximately 450 children) takes this one 
step further by excluding cranial irradiation 
altogether, irrespective of risk category. 
Additionally, for the standard-risk patients, 
anthracyclines which are implicated in the 
development of cardiac failure and second 
cancers, are also completely omitted. 
UMMC is a collaborating site for the 
European BMT-FORUM trial which removes 
total body irradiation and also the alkylating 
drug cyclophosphamide, hitherto ‘standard’ 
Photomicrograph of bone marrow (MGG, 200X). Despite almost identical morphology, lymphoblasts have heterogenous 
biology. Children with ALL require individualized therapy to achieve a balance between cure and toxicity.
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components of the transplant conditioning 
regimen; instead, using alternatives with 
lesser late effects. This is an attempt to avoid 
gonadal failure and subsequent neoplasms 
in children and adolescents with relapsed 
and refractory leukaemia undergoing bone 
marrow transplantation. 
Central to the activities of the UMMC paediatric 
oncology unit has been the Paediatric 
Oncology Research Laboratory; now in its 15th 
year of existence. This laboratory is funded by 
a combination of charitable donations and 
research grants. It provides the necessary 
laboratory support to facilitate the on-going 
collaborative clinical trials and also serves 
as the research hub for the unit whose main 
remit is to deliver high-quality therapies for 
Malaysian children with various malignancies.
The singular objective of curing a child 
with cancer is no longer adequate. Today, 
the challenge for the paediatric oncology 
community is to look beyond the mere 
search for new curative options; instead, 
their role is to champion good quality of 
life for CCS throughout their adulthood by 
making therapies not only effective but more 
importantly, safer. It is this dual goal that 
forms the ethos of the doctors and scientists 
of the UMMC paediatric oncology unit and is a 
duty cherished.
Researchers from the Department of Nursing Sciences, Faculty of Medicine, 
have been actively involved in studying the 
needs of patients who are undergoing cancer 
treatment. This article shares some of their 
important findings on various aspects related 
to communication, lifestyle practices and 
complementary therapy involving the patients.
Cancer and chemotherapy are sources 
of anxiety and worry for cancer patients. 
Communication is thus vital because 
appropriate and accurate information may 
assist the patients to understand the expected 
outcomes and to deal with the unfamiliar 
experience. In a longitudinal study, the team 
found that breast cancer patients exhibit a 
strong need for information at the beginning 
and mid-course of chemotherapy. They hope 
to receive more information pertaining to the 
disease and treatment relative to information 
from the subscales of physical care, 
investigative tests, and psychosocial needs. 
The results provided extremely valuable 
insights for doctors and nurses in dealing 
with cancer patients. An informational needs 
assessment should therefore precede the 
information giving sessions. A paradigm shift, 
with an emphasis on patients as the central 
focus, is needed to enhance the information 
DR CHUI PING LEI
DEPARTMENT OF NURSING SCIENCES
PATIENTS’ NEEDS ASSESSMENT IN CANCER CARE
COMMUNICATION: WHAT DO PATIENTS 
WANT TO KNOW?
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Dr Chui Ping Lei presented research findings at the East Asian Forum of Nursing Scholars in Chiba, Japan. 
giving sessions based on the perception of 
the patients’ themselves. Currently, a study 
on cancer patients’ unmet supportive care 
needs (psychological, health system and 
information, physical and daily living, patient 
care and support, and sexuality) during 
chemotherapy is in progress. 
 
The team showed in a local study more than 
half of breast cancer patients undergoing 
chemotherapy were identified as CAM users. 
The main reason for using CAM was to improve 
emotional well-being, recommendation 
by others and to assist in treating cancer 
respectively. The most common CAM use 
was mind-body practices, followed by natural 
COMPLEMENTARY ALTERNATIVE 
MEDICINE (CAM) USE AMONG CANCER 
PATIENTS DURING CHEMOTHERAPY 
products, and traditional medicine. Many 
patients perceived mind-body practices to 
be beneficial for improving overall well-being 
during chemotherapy. This finding is rather 
encouraging as mind-body practices are non-
ingested therapies, and some of the therapies 
are relatively simple to learn, inexpensive and 
can easily be integrated into daily life. 
An open discussion regarding CAM use, and 
specifically regarding the differences between 
mind-body practices, natural products and 
traditional medicine will empower patients 
to understand the potential benefits and 
anticipate potential adverse effects from CAM 
usage that may interfere with the therapeutic 
effects of chemotherapy. Currently, a study to 
examine the effects of mindful breathing on 
perceived stress and psychological well-being 
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of patients with cancer during chemotherapy 
is in progress.  
An experimental study was conducted to 
evaluate the effect of oral cryotherapy on 
the prevention of oral mucositis and pain 
among colorectal cancer patients undergoing 
fluorouracil-based chemotherapy. The findings 
of the study reveal that 30 minutes of oral 
cryotherapy during chemotherapy followed 
by sodium bicarbonate mouthwash (3 times 
daily) post-chemotherapy until the next 
cycle can improve its efficacy for preventing 
and managing oral mucositis. This finding 
supports the use of oral cryotherapy which 
is cost-effective and has few side effects 
as a preventive strategy. Prevention of oral 
mucositis can help patients adhere to optimal 
chemotherapy dosages and reap the full 
benefits of therapy with minimal discomfort.
 
Nurses as role models for healthy living are 
often expected to be aware of the cancer 
risk factors and translate health-promoting 
behaviours into own self-care. The team 
found that the awareness of lifestyle-related 
cancer risk factors among nurses remained 
alarmingly low. They adopted a moderate 
health-promoting lifestyle. The highest score 
was in spiritual growth subscale while the 
lowest score was on physical activity subscale. 
This finding has provided a useful insight into 
the current health behaviours of nurses. It can 
be used as an important indicator as to where 
education and supportive services may need 
to be targeted.
AWARENESS ON LIFESTYLE-RELATED 
CANCER RISK FACTORS AND 
HEALTH-PROMOTING BEHAVIOURS 
AMONG NURSES
ORAL CRYOTHERAPY: PREVENTION 
FOR ORAL MUCOSITIS AND PAIN 
DURING CHEMOTHERAPY?
Specific cancers are represented by one or 
more ribbon colours to raise awareness.  Some 
common examples are as follows: 
Lavender: All cancers
Pink: Breast cancer
Purple: Pancreatic cancer
Light blue: Prostate cancer
Grey: Brain cancer
White: Lung cancer
Black: Melanoma
Yellow: Sarcoma, bone cancer
Gold: Childhood cancer
Orange: Leukaemia, kidney cancer
Teal & white: Cervical cancer
*Specific cancer may be represented by more than one ribbon colour. Some ribbon colours may also be shared by different cancers. 
Image: Sewcream/Shutterstock.com
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Breast cancer research in University of Malaya 
has always had a multidisciplinary focus 
ranging from public health, clinical trials to 
precision medicine. The team aims to produce 
evidence for the advancement of humanity 
and specifically to improve breast cancer 
outcomes in Malaysia. In 2012-2016, the group 
was awarded the HIR grant which produced 96 
Tier 1 papers, 10 PhD’s and 4 Master students. 
Beyond HIR, the group has remained active in 
various research and community activities, 
highlighted as follows:
GENETICS RESEARCH
Collaboration with Cancer Research Malaysia 
(CRM) led by Adjunct Professor Teo Soo 
Hwang has brought our knowledge on the 
prevalence of BRCA 1, 2 and other hereditary 
genes in Malaysia through the Malaysian 
Breast Cancer Genetics Study (MyBRCA) 
incepted in 2003.  High-risk individuals and 
PROFESSOR DR NUR AISHAH BINTI 
MOHD TAIB
DEPARTMENT OF SURGERY
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BREAST CANCER RESEARCH: BRIDGING LABS, CLINICS AND COMMUNITY 
their family members are managed by the 
Risk Management Clinic since 2009 by a team 
of senior consultants, and Risk Assessment 
Clinic since 2016 in collaboration with UMMC 
Medical Genetics Unit (headed by Professor 
Thong Meow Keong). 
The genetics group has been awarded the 
Wellcome Trust and Newton Fund to study 
genes that can identify at-risk individuals 
in the population through GWAS, hence, 
bringing precision screening to Malaysia. UM 
has contributed patients in this large study 
through the UMMC mammogram cohort in 
collaboration with Professor Kartini Rahmat, Dr 
Farhana Fadzli and Professor Ng Kwan Hoong 
from the Department of Biomedical Imaging. 
Bio-specimens and clinical data of cancer 
patients and controls were banked for research 
purposes. Using case-control design, Vitamin 
D as a risk factor has been studied. Biomarkers 
in early detection study are currently underway 
with Professor Onn Hashim’s proteomics team 
at the Department of Molecular Medicine.
Show you care, be aware - Partnered with Worldwide Breast Cancer, Professor Nur Aishah and her team aim to promote 
early detection of breast cancer through an innovative, effective breast health education.
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CLINICAL TRIALS
The Phase 1b studies for Curcumin 
has been completed and currently the 
study for Tocotrienol is underway for its 
immunomodulatory effects on breast cancer. 
In UMMC, Intraoperative radiotherapy (IORT) 
equipment has also been provided to low-
risk patients, and in 2017, UMMC became a 
participating site in a multicenter randomised 
controlled clinical trial (TARGIT B trial) to 
study the efficacy of IORT boost compared to 
external beam boost in high-risk patients. This 
study is currently recruiting respondents and is 
implemented by the UMMC IORT working group. 
IMPLEMENTATION RESEARCH
Point of care data capture in Electronic 
Medical Records (EMR) and Machine 
Learning using Breast Cancer Data: In 2011 
the UMCRI database initiative was started 
and produced a standalone data system. In 
2015, EMR point of care data capture in the 
Breast Surgery Unit was done in collaboration 
with the Bioinformatics Lab leader, Associate 
Professor Sarinder Kaur and UMMC Jabatan 
Teknologi Maklumat. The research proforma 
had been successfully digitised and mapped 
to the clinical workflows, winning this 
group the prototype research grant entitled 
“Multidisciplinary Point of Care Data Capture 
for Innovative Healthcare: The i-Pesakit Breast 
Cancer Module Prototype, enhancement of the 
University Malaya Medical Centre i-Pesakit 
Electronic Medical Records”. 
The main objective of this implementation 
study is to auto-populate the National Cancer 
Registry form and research database. The 
automation of cancer registry reporting would 
be cost-effective in understanding institutional 
case mix and outcomes. Using new machines 
EPIDEMIOLOGICAL & PROGNOSTIC STUDIES 
UMMC legacy data of about 8000 datasets 
incepted in 1993 by Emeritus Professor Yip 
Cheng Har has led to the first breast cancer 
outcome studies in Malaysia. The data was the 
first to show an improvement in survival by time 
periods and the prognostic effect of ethnicity. 
Currently, the project is led by Associate 
Professor Nirmala Bhoo Pathy (Department of 
Social and Preventive Medicine) who is also 
the principal investigator of the Singapore-
Malaysia Breast Cancer Working Group. 
SURVIVORSHIP RESEARCH
Results from these outcome studies brought 
about the impetus to study lifestyle factors, 
resulting in an ambitious cohort study: the 
Malaysian Breast Cancer Cohort (MyBCC) 
study (PI: Professor Nur Aishah Taib, 
Coordinator: Dr Tania Islam). This cohort 
study reviews patients at 6 months, 1 year and 
3 years and collects information on lifestyle 
factors, anthropometry and clinical data. 
The financial burden on cancer patients 
is also studied under the ASEAN CosTs In 
ONcology(ACTION) study, which comprises 
~10,000 survivors from eight low- and middle-
income Southeast Asia countries including 
Malaysia (PI: Professor Yip Cheng Har and 
Associate Professor Nirmala Bhoo Pathy).
HEALTH SYSTEMS RESEARCH
In collaboration with Ministry of Health, the group 
has shown a high incidence of late presentation, 
diagnosis delay and treatment delay for breast 
cancer in 6 public hospitals. Non-adherence to 
Tamoxifen is as high as 30 % in the first year. 
This study is the first to show disparities in care 
across the public sector in Malaysia.
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and deep learning techniques on archived data 
are also being tested to produce a new way 
for survival and outcome analysis to uncover 
unknown associations with prognostic factors. 
QUALITY IMPROVEMENT PROJECT
A research in collaboration with Infection 
Control Department to reduce mastectomy 
surgical site infection through SSI prevention 
bundle in UMMC was started in 2017. 
COMMUNITY ENGAGEMENT
The team has partnered with AVON Malaysia 
in providing RM 100 000.00 charity funds 
to provide the underprivileged with access 
to diagnosis. Partnered with Worldwide 
Breast Cancer, the group aimed to promote 
early detection of breast cancer through an 
innovative, effective breast health education 
“Know Your Lemons”, in conjunction with 
the 4th UMMC Public Forum. The 5th UMMC 
Public Forum (2018) will focus on “Genes and 
Cancer” in collaboration with “Jean for Genes” 
Group to hold a breast cancer awareness 
campaign and to promote breast health 
literacy among UMMC nurses.
For further details regarding breast cancer research, 
please contact Professor Nur Aishah Taib at: 
naisha@um.edu.my 
Professor Dr Nur Aishah Taib and Datuk Professor Dr Awang Bulgiba b. Awang Mahmud at the 
4th UMMC Breast Cancer Public Forum
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Cervical cancer is one of the top three most common cancers in Malaysian women 
with four out of five cases occurring in women 
between 15 to 64 years of age. Worldwide, 
cervical cancer remains one of the gravest 
threats to women’s lives with one woman dying 
of cervical cancer every two minutes.  This 
need not be the case as cervical cancer is one 
of the most preventable and treatable forms of 
cancer if detected early, managed effectively, 
and with the use of HPV vaccination.
While Malaysia is internationally recognized 
and praised for its successful national school-
based HPV vaccination programme which 
was implemented in 2010, the impact of HPV 
vaccination on cervical cancer incidence and 
mortality may not be realized for decades. To 
significantly reduce the incidence of cervical 
cancer and make it a rare disease in Malaysia, 
an organized cervical screening programme 
that improves coverage and effectiveness is 
urgently required. The uptake of Pap smears 
in Malaysia is low despite campaigns and 
accessible healthcare facilities. The National 
Health & Morbidity Survey (NHMS) 2011 survey 
reported only 12.8% of eligible Malaysian 
women have had a Pap smear within the last 12 
months. Barriers to cervical screening include 
‘patient factors’ such as fear, embarrassment, 
inconveniences and ‘health system factors’ 
including inadequate screening infrastructure 
and human resources for conventional 
pap smear.
In June 2018, Dr Tedros Adhanom 
Ghebreyesus, WHO Director-General issued a 
‘call for coordinated action globally to eliminate 
cervical cancer’. The World Bank has endorsed 
HPV vaccination and HPV-based cervical 
screening as ‘best buys’ for cancer control in 
LMICs. Cervical screening with HPV testing is 
RESEARCH IMPACT ON COMMUNITY
PILOT PROJECT ROSE – REMOVING OBSTACLES IN CERVICAL SCREENING: 
DESIGN THINKING APPLIED TO CERVICAL SCREENING IN MALAYSIA
research impact on community
Training session at one of the participating community clinics. 
PROFESSOR DR WOO YIN LING
DEPT OF OBSTETRICS & GYNAECOLOGY
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a scientifically validated and globally accepted intervention for identifying women at the pre-
cancerous stage and enabling early treatment for cancer prevention.  A Malaysian Integrated 
Cervical Cancer Control Programme of high-coverage, simple screening in 30 to 60 years old 
women, in addition to adolescent HPV vaccination, would not only more rapidly reduce the burden 
and cost of treating cervical cancer, but would serve as a critical model for the region. Hence, a 
novel cervical screening programme was developed using the principles of design thinking. 
The proposed implementation model is being proven through a successful and innovative 
collaborative trial led by University of Malaya with global multidisciplinary experts in the field 
– Pilot PROJECT ROSE – Removing Obstacles in cervical ScrEening. Key components are: 
Self-sampling of women, HPV DNA testing, and digital e-Health platform for high connectivity 
to participants and real-time reporting. Pilot PROJECT ROSE is informing the road-map for 
implementation and scale-up of a phased, feasible, cost-effective, and sustainable national 
cervical cancer screening programme which complements the very successful HPV vaccination 
programme in Malaysia. Malaysia can be the first country in South East Asia to implement a 
population-wide, highly effective cervical cancer screening program, in conjunction with the 
leading HPV vaccination programme, establishing leadership to other countries in our region.
Editor’s note: Recently, Project ROSE, led by Professor Woo Yin Ling has been shortlisted as one of 
the three finalists for the 2018 UICC (Union for International Cancer Control) Collaborative Award. This 
prestigious award aims to identify and celebrate best practices across UICC members and inspire the 
cancer control community. The award recognizes collaborative initiatives, whether national, regional 
or international, that exhibit innovative models of engagement and outcomes. PULSE@UM wishes the 
team every success.
For more information about cervical cancer prevention and Project ROSE, visit: 
https://www.facebook.com/ProjectROSE.my/
research impact on community
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CURRENT MALAYSIA PAP SMEAR PROGRAM
Opportunistic
Requires Pelvic Examination by healthcare professional: known barrier to screening uptake
Suboptimal uptake of screening
No formal monitoring or recall system for positive results
Will require up to 15 tests in a woman’s lifetime
Health costs forecast to increase in the next 10 to 20 years
SELF-SCREENING PILOT PROGRAM (PILOT PROJECT ROSE)
Self-acquired screning test
HPV screening for the highest test sensitivity
Can be effective with two to five tests in a lifetime
Health portfolio budget savings over the long term
Backed by an advanced e-Health platform (registry) to provide real-time information quickly, 
accurately and securely within an Azure environment
CUSTOMIZED E-HEALTH SOLUTION
Scalable with population growth and configurable to new testing and treatment schedules 
(i.e.: HIV and Hepatitis C)
Promotes a framework for reporting of full programme information to Government (positivity 
rates, follow-up rates etc.)
Leverages mobile technology for high connectivity ensuring women are not lost for follow-up
26
The applications of nanotechnology in our daily living are vast, spanning over a 
number of sectors including food, medicine, 
consumer appliances, electronics, civil, 
military, etc. According to BBC Research, 
the global nanotechnology market may 
reach $90.5 billion by 2021 at a compound 
annual growth rate of 18.2% from present. 
In the field of medicine, the application of 
nanotechnology in improving the efficacy and 
safety of anticancer chemotherapeutic drugs 
is rapidly expanding. 
Chemotherapeutic drugs are low molecular 
weight cytotoxic drugs that destroy tumour 
tissue through several mechanisms that 
interfere with cellular functions and cell 
replication, and they have been routinely used 
for curative, adjuvant or palliative treatments 
of cancer of all stages. However, the effective 
use of anticancer drugs is often hampered by 
their low therapeutic indices because of their 
uncontrolled dissemination in the body post-
administration (Figure 1). Such undesirable 
drug dissemination reduces the amount of drug 
INNOVATION AND TECHNOLOGY
FROM NANOTECHNOLOGY TO NANOTHERAPEUTICS: 
IMPROVING ANTICANCER CHEMOTHERAPY
innovation and technology
ASSOCIATE PROFESSOR DR KIEW LIK VOON DEPARTMENT OF PHARMACOLOGY, 
FACULTY OF MEDICINE, UNIVERSITY OF MALAYA
PROFESSOR DR CHUNG LIP YONG DEPARTMENT OF PHARMACY, FACULTY OF 
MEDICINE, UNIVERSITY OF MALAYA
ASSOCIATE PROFESSOR DR YEONG CHAI HONG SCHOOL OF MEDICINE (MEDICAL 
PHYSICS), FACULTY OF HEALTH AND MEDICAL SCIENCES, TAYLOR’S UNIVERSITY
Fig. 1. Uncontrolled dissemination of anticancer in the body post-administration.
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reaching the tumour and its metastases. At 
the same time, it causes non-specific toxicity 
to normal tissues and leads to adverse effects 
including myelosuppression, neurotoxicity, 
gastrointestinal disturbances, hair loss, 
and death. 
For chemotherapeutic drugs to exert maximal 
anticancer efficacy and low adverse effects, 
they have to be selectively delivered to 
the tumour without random dissemination 
in the body. Such an ideal scenario can 
potentially be achieved via the assistance 
of nanotechnology. The use of active and 
passive-targeted nanodrug-delivery systems 
for selective tumour-drug-delivery is chiefly 
rooted in the key phenomenon of “enhanced 
permeability and retention (EPR) effect”, that is, 
the hyperpermeation and prolonged retention 
of macromolecular-sized nano-carrier-drug-
complexes within the tumour tissues due to 
the aberrant anatomical features found in a 
number of solid tumours, i.e. leaky vasculature 
with multiple blood capillary fenestrations at 
the diameter of 380-780 nm, coupled with the 
lack of functional lymphatic drainage.
This discovery of EPR in 1986 has helped 
to kick-start a rapid development of 
nano-carrier-assisted tumour delivery of 
chemotherapeutic drugs. In the past three 
decades, various clinical chemotherapeutic 
drugs were integrated into a great variety of 
biocompatible nano-carriers to form drug-
loaded nanotherapeutics, and were tested 
both in vitro and in vivo. Currently, a number 
of the first generation nanotherapeutics (with 
one drug species housed within one nano-
carrier structure as the common feature, 
Figure 3), such as Abraxane®, Doxil®, 
Myocet®, Genexol-PM®, etc. have passed 
clinical trials and entered into the market. As 
these nanotherapeutics received approval for 
clinical use, new generation nanotherapeutics 
are under development and are ready for 
clinical trials. However, only a handful of the 
new generation nanotherapeutics managed 
to enter into clinical trials successfully, due 
to the complexity in the development of 
policies on nanotoxicity/nanosafety, obtaining 
the necessary approval for clinical trial and 
the shortage of funding. In light of this, 
establishment of clear regulatory policies on 
nanotoxicity/nanosafety and clinical trials 
related to nanotherapeutics is necessary.
In Malaysia, although the field of 
nanotherapeutics research is still in its infancy, 
numerous developmental efforts from local 
universities have been reported over the past 2 
decades. In the Faculty of Medicine, University 
of Malaya, a small group of researchers 
Fig. 2. Nano-carrier-drug-complexes for selective tumour-drug-delivery.
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from the Nanotherapeutics Lab (NTL) has been progressing well in the development of new 
generation anticancer nanotherapeutics and nano-drug-carriers for active and passive tumour 
delivery of anticancer drugs and imaging probes. Some of the notable products developed 
by the team include high-drug-payload nanotherapeutics, immuno-stealth-nanotherapeutics, 
free-radical-generating near-Infrared (NIR)-photodynamic nanotherapeutics, photothermal 
nanotherapeutics, etc. Although good progress is seen in the nanotherapeutics research both 
from within UM and respective institutions across Malaysia, greater investments from the 
public and private sectors are still very much needed not just to further excite the growth of 
the field, but also to encourage coalition among the local research groups and companies for 
greater advancements.
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The Science Café held on April 23, 2018 
showcased the research activities under 
the Public Health and Non-communicable 
Diseases Research Thrust, with a focus on 
programmes relating to “Child, Adolescent, 
and Young Adult Health”. Associate Professor 
Dr Noran Naqiah bt Mohd Hairi, head of 
the research thrust, explained that the aim 
of the programmes is to determine the 
social and environmental determinants of 
health issues of children, adolescents and 
young adults in Malaysia and to help these 
younger Malaysians to improve and sustain a 
healthy lifestyle. 
Associate Professor Dr Hazreen Abdul 
Majid (Department of Social and Preventive 
Medicine) and Associate Professor Dr 
Muhammad Yazid Jalaludin (Department of 
Paediatrics) who are heading the Malaysian 
Health and Adolescents Longitudinal 
Research Team (MyHeART) described the 
prevalence of cardiovascular risk factors 
among adolescents in Peninsular Malaysia. 
The MyHeART group is interested in 
determining how lifestyles during early 
adolescence can have an effect on 
cardiovascular, lung, and bone health in early 
adulthood. Furthermore, the psychological 
and social factors that influence ‘high risk’ 
behaviours during young adulthood are also 
studied. Associate Professor Dr Muhammad 
Yazid also shared his clinical research findings 
from the MyBFF@school project (My Body is 
Fit and Fabulous@school project), which is an 
intervention study to combat obesity among 
school children.
Associate Professor Dr Moy Foong Ming 
(Department of Social & Preventive Medicine) 
subsequently shared with us the project on the 
assessment of sustainable diet among young 
adults. Through activities such as sharing 
of meals photos, the team was able to get a 
glimpse into the diets of Malaysian youth. 
Data from this study will help formulate dietary 
recommendations for the younger Malaysian 
public to address the broader environmental 
and social issues of sustainability.
The Malaysian Care for Adolescent Project 
(MyCAP) was presented by Dr Rafdzah Ahmad 
Zaki and Dr Nik Daliana Nik Farid from the 
Department of Social & Preventive Medicine. 
One of the main objectives of the project is 
to deliver effective sexual and reproductive 
health education to adolescents especially the 
poor, marginalized youth. An Internet-based 
programme for information dissemination 
has been developed to improve sexual and 
reproductive health (SRH) knowledge among 
Malaysian adolescents.  The online approach 
will be complemented with conventional face-
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to-face discussions regarding sexual health. 
 
Last but not least, Associate Professor Dr Claire 
Choo Wan Yuen (Department of Preventive 
and Social Medicine) presented on behalf of 
Associate Professor Dr Sajaratulnisah Othman 
(Department of Primary Care Medicine) on 
their experiences in running the Community-
Academic Programme (CAP), a programme 
designed for ‘Supporting Youth Against 
Violence & Unhealthy Sexual Activities’ in 
collaboration with Klinik Kesihatan Taman 
Medan (MoH), All Women’s Action Society 
(AWAM) and Pusat Aktiviti Kanak-kanak 
(Social Welfare Department). The programme 
included important workshops to examine 
the level of understanding amongst the youth 
about gender-based violence (GBV) and sexual 
reproductive health (SRH) issues, as well as 
running various activities to promote self-
esteem, knowledge, attitudes, and skills related 
to healthy relationships and adolescent SRH. 
For more information, please contact Research 
Management Centre (03-79677515).
The Science Café session held on 30th May, 2018 themed “Drugs, nanomaterials and venoms: 
When toxicity is a concern” showcased selected niche area research in the faculty. The session 
began with Dr Shamsul Mohd Zain from the Pharmacogenomics Laboratory, Department of 
Pharmacology. Dr Shamsul revealed that some medicines can turn toxic even though when the 
dosage taken by the patient is within the normal therapeutic range. This is largely due to the 
genetic makeup of certain people that makes them susceptible to the drug adverse effects. 
However, the study of genes and their association with adverse drug reaction (ADR) is often 
not feasible in the country as the study usually requires a large sample size. Furthermore, 
the incidence of certain ADR is relatively low and genetic variants exist among patients. To 
overcome this challenge, an international collaborative work has been set up: The South East 
Asian Pharmacogenomics Network (SEAPharm). SEAPharm has recently launched a kick-off 
project with a focus on carbamazepine-induced severe cutaneous adverse reactions (SCARs). 
The project aims to improve the guideline for the clinical implementation of a pharmacogenomics 
panel suitable for the Southeast Asian populations in ADR prevention. Research conducted by 
Dr Shamsul and his team will contribute to this international collaboration through sampling and 
analysis of the Malaysian patients.
The talk was continued by Dr Leo Bey Fen from the Central Unit for Advanced Research Imaging 
(CENTUARI). In her talk, Dr Leo shared with the audience the advancement of nanotechnology 
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in health and medical practice. Nanomaterials or nanoparticles have been used frequently for 
therapeutic purposes, for instance, in drug delivery to improve the efficacy and safety profile of 
anticancer drugs. Recently, the research findings from her team have shown many promising 
health benefits of silver nanoparticles, such as the reduction of brain inflammation and 
neurotoxicity; however, nanomaterials are not without toxicity, and this is an important emerging 
topic to be addressed by nanotechnology researchers. Dr Leo and team are currently working on 
characterizing nanoparticle toxicity and how this can be mitigated.  
Dr Tan Choo Hock from the Venom Research and Toxicology Lab, Department of Pharmacology, 
subsequently talked on venom and antivenom research conducted by his team. Snakebite 
envenomation remains a WHO-listed neglected tropical disease and Dr Tan’s team has been 
actively working on the profiling of various snake venoms using an integrated proteomic and 
pharmacological approach, in order to better understand the correlation between venom 
composition, the mechanistic actions of toxins, and the pathophysiology of envenomation. 
Antivenom shortage is another challenge faced in the management of snake envenomation. 
Currently, several international collaborations have been established with Dr Tan’s lab to study 
ways of improving antivenom quality and supply in the region. 
For more information, please contact Research Management Unit (03-79677515).
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The Science Café session held on 16th May showcased research and initiatives on “Patient-
centred care” by clinicians and researchers clustered under the Cancer and Drug Discovery 
Research Thrust. Professor Nur Aishah Mohd Taib (Department of Surgery), who is also the 
thrust leader, chaired and started the session by sharing that healthcare providers treat patients 
not only from a clinical perspective, but also from an emotional, mental, spiritual, social and 
financial perspective. To address this holistic management approach in particular for cancer 
patients, various studies have been conducted by FOM investigators and their collaborators, and 
the topics involved can be categorically divided into “Early Survivorship” and “Late Survivorship”. 
First, Dr Tania Islam (Department of Surgery) shared the findings with the audience about 
the development of a breast care nurse-led video orientation programme on information 
and navigation for newly diagnosed breast cancer patients at UMMC, which has effectively 
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improved the patients’ knowledge and satisfaction. The programme also enhanced cancer care 
coordination among departments and the patient experience in UMMC. 
Dr Chui Ping Lei (Department of Nursing) subsequently presented an on-going project on the 
effects of mindful breathing on perceived stress and mindfulness among cancer patients. Ms 
Stella Kong Yik-Ching (National Clinical Research Centre, MOH) presented the team’s findings on 
financial needs of breast cancer patients in Malaysia, and the various coping strategies patients 
have adopted. Dr Caryn Chan Mei Hsien (Universiti Kebangsaan Malaysia) also explored the 
psychological distress faced by cancer patients and her collaboration with FOM researchers in 
conducting a trial of psycho-educational intervention for the patients. These studies highlighted 
the need for care and support to be extended to those patients in the early stage of cancer 
diagnosis and management.  
The session continued with Ms Yoon Sook-Yee (Head of Familial Cancer, Cancer Research 
Malaysia) on the success of the national genetic study, “Mainstreaming Genetic Counselling” 
for genetic testing of BRCA1 and BRCA2 in Malaysian Ovarian Cancer Patients (MaGic Study), 
and psycho-social research on patients and their families. Ms Hamizah Sa’at (Department of 
Surgery) also presented her study on the exploration of decisional needs in Malaysian BRCA 
carriers in opting for risk-reducing salpingo-oophorectomy. The decision quality can be improved 
with better patient’s knowledge, well-facilitated communication with doctor and reduced 
decisional conflicts. Ms Grace Yeoh Kar See (Department of Surgery) subsequently presented 
her PhD study on clinicians’ perspectives on breast cancer risk management for BRCA mutation 
carriers in Malaysia. A patient decision aid is important to provide communication and delivery 
of personalised cancer risk management to BRCA carriers in Malaysia. 
Lastly, Dr Lee Yew Kong (Department of Primary Care Medicine) shared with the audience his 
research on coping strategies of Malaysian women with recurrent ovarian cancer. It was found 
that the coping strategies were mostly in place for the women interviewed, and the strategies were 
unique to the Malaysian setting where there is a strong religious element and family involvement. 
For more information, please contact Research Management Unit (03-79677515).
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June is National Cancer Survivors Month in  the 
USA and several other countries. 
Information on cancer support groups in 
Malaysia is available here:
https://www.cancer.org.my/about/what-we-do/
support/support-groups/
Image: Rawpixel.com/Shutterstock.com
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Although there has been limited data on teen-
age pregnancy in Malaysia, the increasing 
reports on incidences of abandoned babies 
indicate that increased premarital sexual in-
tercourse resulted in unwanted pregnancies 
among unmarried adolescents.  This consul-
tancy report commissioned by the National 
Population and Family Development Board, un-
der the  Ministry of Women,  Family and Com-
munity Development Malaysia, deals with the 
risk and protective factors affecting adoles-
cents’ sexual and reproductive health (SRH) in 
East Malaysia (Sabah and Sarawak) for effec-
tive policy and programme advocacy.  
Different cultures in the East Malaysian region 
may influence the risk and protective factor 
affecting young Malaysian SRH there.  Infor-
mation for this study was obtained from ado-
lescents aged 13 to 24 years which included 
school students, college/university students 
and out-of-school adolescents. Information 
gathered include knowledge, attitudes and 
practices related to sexual and reproductive 
health as well as risk and protective factors 
against premarital sex among adolescents in 
Sabah and Sarawak.  
Overall, the protective factor against premarital 
sex for school adolescents is strong religious 
beliefs, while for the college/university stu-
dents, the protective factors are having good 
knowledge and positive attitudes toward sexu-
al and reproductive health.  Whereas for out-of-
school adolescents, the protective factors are 
having high self-evaluation and involvement in 
community activities.  The findings will provide 
policy makers and state implementers with a 
clear picture of the adolescent SRH situation 
in East Malaysia to help better address specif-
ic SRH issues in the states.  The information 
gathered is crucial for public awareness on the 
adolescent SRH situation that needs attention 
and appropriate interventions to ensure the ho-
listic development of adolescents and youth.  
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AUTHORS: LOW WAH YUN, HALIMAH 
AWANG, CHEAH WHYE LIAN, CHANG CHING 
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Madam Faizatul Lela Jafar (Department of Medical 
Microbiology): International Federation of Biosafety 
Associations (IFBA)’s 2017 Biosafety Heroes.
Dr Sim Joong Hiong (Medical Education & 
Research Development Department): Association 
of Commonwealth Universities Fellowship Award.
Associate Professor Dr Veera Sekaran Nadarajan 
(Department of Pathology): Regional Director for 
the Western Pacific region, International Society of 
Blood Transfusion (ISBT).
Madam Vishala Sivapalan (Department of 
Pharmacology): 2nd runner-up, 2018 Famelab 
National Championship on science communication. 
Associate Professor Dr Tengku Ain Fathlun 
(Department of Ophthalmology) and Dr Wong Won 
Fen (Department of Microbiology): 2018 Fulbright 
Malaysia Scholar Program.
Dr Cindy Teh (Department of Medical Microbiology): 
Malaysian Society for Infectious Disease and 
Chemotherapy (MSIDC) - Institut Mérieux Young 
Investigator Award 2018.
Faculty of Medicine Neuroscience Best Publication 
Awards: Associate Professor Dr Vairavan Narayanan 
(Department of Surgery) and Dr Tan Soon Hao 
(Department of Biomedical Sciences).
Professor Dr Suresh Kumar Govind (Department 
of Parasitology), Dr Chandramathi Samudi@Raju 
(Department of Medical Microbiology) and Dr 
Rukumani Devi Velayuthan (Department of Medical 
Microbiology): Silver Medal, 46th International 
Exhibition of Inventions, Geneva. 
Professor Dr Lydia binti Abdul Latif (Department Of 
Rehabilitation Medicine), Associate Professor Dr 
Farizah binti Mohd Hairi (Department of Social & 
Preventive Medicine) and Professor Dato Dr Zaliha 
Omar (UMSC): Special Award of High Impact Project 
(Anugerah Khas Projek Berimpak Tinggi), UMCares.
Dr Phan Chia Wei (Department of Pharmacy) and 
Professor Dr Murali Naidu (Department of Anatomy): 
Winner of the Health Cluster (Pemenang Kluster 
Kesihatan), UMCares.
Project ROSE, led by Professor Dr Woo Yin Ling 
(Department of Obstetrics and Gynaecology): 
finalists for the 2018 Union for International Cancer 
Control Collaborative Award. 
*A complete list will follow in the next issue.
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PULSE@UM WOULD LIKE TO CONGRATULATE THE FOLLOWING AWARD 
WINNERS FROM THE FACULTY:
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SEPTEMBER 2018
6-7 September
Python Intermediate for Data Analytics
18-19 September
Managing Your References using EndNote
20-21 September
Qualitative Methodology Research in Health
Contact: Research Management Unit (RMUFOM), 
rmctraining@um.edu.my 
20-22 September
Kuala Lumpur Innovation Forum
Contact: Dr Leo Bey Fen, CENTUARI, beyfenleo@
um.edu.my
OCTOBER 2018
8-12 October
FOM eHealth Research Carnival
Contact: Dr Teo Chin Hai, Department of Primary 
Care Medicine, teoch@um.edu.my
15-19 October
Bioinformatics Bootcamp
Contact: Research Management Unit (RMUFOM), 
rmctraining@um.edu.my 
UPCOMING EVENTS
NOVEMBER 2018
27-30 November
Qualitative Research in Health Workshop by 
Professor Pranee Liamputtong
Contact: Research Management Unit 
(RMUFOM), rmctraining@um.edu.my
DECEMBER 2018
19-20 December
Understanding Statistical Results in Clinical 
Research
Contact: Research Management Unit (RMUFOM), 
rmctraining@um.edu.my
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